GlycoMimetics, Inc. Stock price

Equities

GLYC

US38000Q1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3 USD -5.66% Intraday chart for GlycoMimetics, Inc. -1.64% +27.12%
Sales 2024 * - Sales 2025 * 34.76M Capitalization 193M
Net income 2024 * -40M Net income 2025 * -31M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 5.56 x
P/E ratio 2024 *
-5.11 x
P/E ratio 2025 *
-11.1 x
Employees 39
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.66%
1 week-1.64%
Current month+3.81%
1 month-0.66%
3 months+20.48%
6 months+102.70%
Current year+27.12%
More quotes
1 week
2.77
Extreme 2.77
3.18
1 month
2.50
Extreme 2.5
3.18
Current year
2.20
Extreme 2.2
3.53
1 year
1.11
Extreme 1.11
3.53
3 years
0.51
Extreme 0.51
4.16
5 years
0.51
Extreme 0.51
13.44
10 years
0.51
Extreme 0.51
26.05
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 21-08-05
Founder 64 03-04-03
Director of Finance/CFO 49 10-01-31
Members of the board TitleAgeSince
Director/Board Member 71 16-03-16
Director/Board Member 66 17-06-11
Director/Board Member 59 18-11-27
More insiders
Date Price Change Volume
24-03-28 3 -5.66% 648,130
24-03-27 3.18 +11.58% 675,049
24-03-26 2.85 +1.06% 227,069
24-03-25 2.82 -3.75% 320,276
24-03-22 2.93 +1.74% 205,631

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3 USD
Average target price
7 USD
Spread / Average Target
+133.33%
Consensus
  1. Stock
  2. Equities
  3. Stock GlycoMimetics, Inc. - Nasdaq